NEW GENERATION BIOMIMETIC AND CUSTOMIZED IMPLANTS FOR BONE ENGINEERING COST Action – MP 1301 – http://www.cost-newgen.org NEW GENERATION BIOMIMETIC AND CUSTOMIZED IMPLANTS FOR BONE ENGINEERING Chair : Dr Francis Cambier Brussels, 9th March 2015

New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING What context ? With a predicted ageing population and increasing expectations regarding quality of life in old age, there is an ever increasing demand for procedures such as total hip replacements, bone reconstructions, and spinal fusions, resulting from conditions such as joint cartilage degeneration and osteoporosis. Due to the gap between academic R&D and commercial production, and between materials scientists and clinicians, medical application of these new materials will never be possible unless companies and medics are involved in the development. This COST Action, NEWGEN, aims at creating the seed for the European research and industry collaboration, combining basic knowledge from academic laboratories, R&D centers, medical units from hospitals, and a significant number of companies

Some figures One third of the population is more than 60 years old in 2010 600.000 hip replacements in Europe /year 150.000 invasive spinal fusions in Europe /year More than 4.000.000 operations involving bone grafting or bone substitutes performed around the world / year Orthopedic biomaterials market : ~ $8 billions (grow rate 5%) US: 42 %, Europe: 31 %

The need of cooperation Design Biomaterials preparation Medical assessment Strong interactions between : Processing R&D Hospital units Producers Characterisations Functionalization In vitro / In vivo testings Fabrication Surgical operation

Multimaterials Biomaterial conception Multipartners Polymers Metals Ceramics Composite Multidisciplinary Engineering Material science Biology Physics Chemistry Medicine Regulations Multipartners Medical certification Regulatory approval Scaling up Commercialisation Lack of communications between R&D, Hospital units and Industry  Unique opportunity to link European researchers to industries and end-users

Objectives, benefits, impacts Establish a structured coordination, helping in the development of the right products. R&D increasing performance Increase of competitiveness of European companies Concrete achievements Multi-partners projects, mainly on new bioactive and customized bone implants, incorporating every aspect of the whole value chain (including H2020 projects) Attraction of an Asian company to Europe Dissemination (1 collective book, papers, Web site)

Consortium of partners 29 COST countries + 3 non-COST countries (USA, Canada, Australia) 141 partners 50% of the consortium members are companies, surgeons/medical units and research centers

How it works COST Office Members Core group Management committee WG 1 Chair/Vice-chair 4 WG Leaders At least 1 by COST country 1 by non-COST participant Core group Management committee Chair, VC, WG leaders GH STSM, Dissemination, Web WG 1 WG 2 WG 3 WG 4 1 WG Leader – 1 vice leader Transversal activities (web page feeding, events organisation, communication, STSMs…) Each WG will consist of partners from academic institutes, industries and medical units

The tools Core group meetings WG meetings Scientific workshops MC meetings (to approve the suggestions) STSM – selection is difficult: 1st quality, ECI , inclusiveness policy countries, gender balance, etc. Summer schools Dissemination – grants, book, papers, etc. http://www.cost-newgen.org

Is it easy ? How to get the support of COST: The language: Pre-proposal (4 pages, web) 30rd Sept 2012  2 experts eligible (10th Oct 2012)  ok for a full proposal (end Nov 2012) Proposal (40 pages) end Jan 2013  experts Selection to present (orally)  DC Hearing in Brussels (40 people, mid March 2013) Decision of DC (9th April 2013)  administrative details to be completed Decision by Cost Office and CSO (end of May 2013)  beginning of signature of MoU by the countries Kick Off Meeting  2nd Oct 2013 (starting date) The language: Everything is in the Vademecum (including a 2 pages lexicon) Examples : WG, STSM, LOS, ECI (was ESR), GH, MC, AO, SO, KOM, CNC, SC, EB, (CSO, DC ?), etc. The role of the grant holder: Follow the rules (Vademecum) while scientists do not understand (or are not willing to do that) A difficulty and advantage: loss of control of the players (members of MC) – but it is a part of the interest  opening to new countries, etc.

Thank you for your attention Conclusion: A very nice experience Thank you for your attention